Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Rhea-AI Summary

Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, has announced its participation in the 2025 BIO CEO & Investor Conference. The event will take place on February 10-11, 2025, at the New York Marriott Marquis.

The company's management will deliver a corporate overview presentation on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room. Throughout the conference, management will be available for one-on-one meetings with registered investors and attendees. Interested parties can schedule meetings through the BIO Partnering portal, while those unable to attend can contact Yvonne Briggs at Alliance Advisors to arrange meetings with management.

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.

Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting with Processa management, please contact Yvonne Briggs at ybriggs@allianceadvisors.com.

About Processa Pharmaceuticals, Inc.

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.

For more information, visit our website at www.processapharma.com.

Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com

Investor Relations Contact:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com

# # #

FAQ

When is Processa Pharmaceuticals (PCSA) presenting at the 2025 BIO CEO Conference?

Processa Pharmaceuticals will present on Tuesday, February 11, 2025, at 10:00 a.m. Eastern time in the Plymouth Room at the New York Marriott Marquis.

How can investors schedule meetings with PCSA management at the 2025 BIO CEO Conference?

Investors can schedule meetings through the BIO Partnering portal if attending the conference. Non-attendees can contact Yvonne Briggs at Alliance Advisors.

Where is the 2025 BIO CEO & Investor Conference being held for PCSA's presentation?

The conference is being held at the New York Marriott Marquis on February 10-11, 2025.

What is the focus of Processa Pharmaceuticals' (PCSA) research and development?

Processa Pharmaceuticals is focused on developing next-generation cancer therapies with improved efficacy and safety.